Cover Image
Market Research Report

Merkel Cell Carcinoma - Pipeline Review, H2 2016

Published by Global Markets Direct Product code 410981
Published Content info 157 Pages
Immediate Delivery Available
Price
Back to Top
Merkel Cell Carcinoma - Pipeline Review, H2 2016
Published: December 30, 2016 Content info: 157 Pages
Description

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Merkel Cell Carcinoma - Pipeline Review, H2 2016, provides an overview of the Merkel Cell Carcinoma (Oncology) pipeline landscape.

Merkel cell carcinoma is a rare aggressive skin cancer that is at high risk of recurring and spreading (metastasizing) throughout the body. Risk factors for Merkel cell carcinoma include age, gender, light skin color, Ultraviolet exposure and immune suppression. Symptom includes painless nodule on skin. It usually starts on areas of skin exposed to the sun (face, neck, arms, and legs). Treatment includes chemotherapy, radiation therapy and surgery.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Merkel Cell Carcinoma - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Merkel Cell Carcinoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Merkel Cell Carcinoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Merkel Cell Carcinoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase II, Phase I and Preclinical stages are 1, 7, 5 and 1 respectively. Similarly, the Universities portfolio in Phase I stages comprises 1 molecules, respectively.

Merkel Cell Carcinoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Merkel Cell Carcinoma (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Merkel Cell Carcinoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Merkel Cell Carcinoma (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Merkel Cell Carcinoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Merkel Cell Carcinoma (Oncology)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Merkel Cell Carcinoma (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Merkel Cell Carcinoma (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Product Code: GMDHC8896IDB

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Merkel Cell Carcinoma Overview
    • Pipeline Products for Merkel Cell Carcinoma - Overview
    • Pipeline Products for Merkel Cell Carcinoma - Comparative Analysis
  • Merkel Cell Carcinoma - Therapeutics under Development by Companies
  • Merkel Cell Carcinoma - Therapeutics under Investigation by Universities/Institutes
  • Merkel Cell Carcinoma - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Merkel Cell Carcinoma - Products under Development by Companies
  • Merkel Cell Carcinoma - Products under Investigation by Universities/Institutes
  • Merkel Cell Carcinoma - Companies Involved in Therapeutics Development
    • Amgen Inc
    • Apcure SAS
    • BeiGene Ltd
    • Immune Design Corp
    • Merck & Co Inc
    • Merck KGaA
    • Millennium Pharmaceuticals Inc
    • NantKwest Inc
    • Novartis AG
    • OncoSec Medical Inc
    • Oncovir Inc
    • Ono Pharmaceutical Co Ltd
  • Merkel Cell Carcinoma - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • aNK Program - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • APC-001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • avelumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BGBA-317 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • DNA IL-12 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • EBC-46 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • G-100 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • nivolumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pasireotide - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pazopanib hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pembrolizumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Poly-ICLC - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • sapanisertib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • talimogene laherparepvec - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Vaccine to Target WT1 for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Merkel Cell Carcinoma - Product Development Milestones
    • Featured News & Press Releases
      • Nov 29, 2016: FDA Accepts the Biologics License Application for Avelumab for the Treatment of Metastatic Merkel Cell Carcinoma for Priority Review
      • Nov 14, 2016: NantKwest Announces Achievement of End Point in Merkel Cell Carcinoma Phase II Trial With Evidence of Efficacy of Activated Natural Killer (aNK) Cells in Solid Tumors
      • Oct 31, 2016: European Medicines Agency Validates the Marketing Authorization Application for Avelumab for the Treatment of Metastatic Merkel Cell Carcinoma
      • Sep 28, 2016: Merck to Present Data on Avelumab at ESMO 2016
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Merkel Cell Carcinoma, H2 2016
  • Number of Products under Development for Merkel Cell Carcinoma - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Investigation by Universities/Institutes, H2 2016
  • Merkel Cell Carcinoma - Pipeline by Amgen Inc, H2 2016
  • Merkel Cell Carcinoma - Pipeline by Apcure SAS, H2 2016
  • Merkel Cell Carcinoma - Pipeline by BeiGene Ltd, H2 2016
  • Merkel Cell Carcinoma - Pipeline by Immune Design Corp, H2 2016
  • Merkel Cell Carcinoma - Pipeline by Merck & Co Inc, H2 2016
  • Merkel Cell Carcinoma - Pipeline by Merck KGaA, H2 2016
  • Merkel Cell Carcinoma - Pipeline by Millennium Pharmaceuticals Inc, H2 2016
  • Merkel Cell Carcinoma - Pipeline by NantKwest Inc, H2 2016
  • Merkel Cell Carcinoma - Pipeline by Novartis AG, H2 2016
  • Merkel Cell Carcinoma - Pipeline by OncoSec Medical Inc, H2 2016
  • Merkel Cell Carcinoma - Pipeline by Oncovir Inc, H2 2016
  • Merkel Cell Carcinoma - Pipeline by Ono Pharmaceutical Co Ltd, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016

List of Figures

  • Number of Products under Development for Merkel Cell Carcinoma, H2 2016
  • Number of Products under Development for Merkel Cell Carcinoma - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top